Q1 2024 EPS Estimates for Henry Schein, Inc. (NASDAQ:HSIC) Lowered by Zacks Research

Posted by on Jun 24th, 2023

Henry Schein, Inc. (NASDAQ:HSIC – Get Rating) – Stock analysts at Zacks Research dropped their Q1 2024 EPS estimates for shares of Henry Schein in a note issued to investors on Wednesday, June 21st. Zacks Research analyst U. Biswas now expects that the company will post earnings of $1.30 per share for the quarter, down from their previous estimate of $1.35. The consensus estimate for Henry Schein’s current full-year earnings is $5.26 per share. Zacks Research also issued estimates for Henry Schein’s Q1 2025 earnings at $1.51 EPS and FY2025 earnings at $6.18 EPS.

Henry Schein (NASDAQ:HSIC – Get Rating) last issued its quarterly earnings data on Tuesday, May 9th. The company reported $1.21 EPS for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.02). The company had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.09 billion. Henry Schein had a return on equity of 15.41% and a net margin of 3.82%. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.30 EPS.

A number of other research analysts have also recently commented on HSIC. Barrington Research reduced their target price on shares of Henry Schein from $92.00 to $90.00 in a research report on Wednesday, May 10th. UBS Group upped their price objective on shares of Henry Schein from $75.00 to $82.00 and gave the company a “neutral” rating in a research report on Tuesday, March 7th. Credit Suisse Group dropped their target price on Henry Schein from $99.00 to $97.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 28th. Finally, StockNews.com downgraded Henry Schein from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $86.14.

Henry Schein Stock Down 1.0 %

NASDAQ HSIC opened at $78.90 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. Henry Schein has a fifty-two week low of $64.75 and a fifty-two week high of $89.72. The business has a 50 day moving average price of $78.00 and a two-hundred day moving average price of $80.35. The stock has a market cap of $10.34 billion, a PE ratio of 22.54, a P/E/G ratio of 2.19 and a beta of 0.83.

Insider Activity

In other Henry Schein news, EVP Mark E. Mlotek sold 24,747 shares of the stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $76.68, for a total transaction of $1,897,599.96. Following the transaction, the executive vice president now owns 69,138 shares of the company’s stock, valued at approximately $5,301,501.84. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, COO Michael S. Ettinger sold 14,881 shares of the business’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $75.12, for a total transaction of $1,117,860.72. Following the completion of the sale, the chief operating officer now owns 75,710 shares of the company’s stock, valued at approximately $5,687,335.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Mark E. Mlotek sold 24,747 shares of the stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $76.68, for a total transaction of $1,897,599.96. Following the sale, the executive vice president now owns 69,138 shares in the company, valued at approximately $5,301,501.84. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 75,019 shares of company stock worth $5,651,018. 1.14% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Henry Schein

Institutional investors have recently made changes to their positions in the stock. Dupont Capital Management Corp boosted its position in Henry Schein by 73.9% during the 4th quarter. Dupont Capital Management Corp now owns 546 shares of the company’s stock valued at $44,000 after purchasing an additional 232 shares during the period. Allworth Financial LP boosted its holdings in shares of Henry Schein by 3,594.1% during the first quarter. Allworth Financial LP now owns 628 shares of the company’s stock valued at $51,000 after acquiring an additional 611 shares during the period. Godsey & Gibb Inc. acquired a new position in shares of Henry Schein during the fourth quarter valued at $64,000. Mirova bought a new position in shares of Henry Schein during the first quarter worth about $66,000. Finally, ANTIPODES PARTNERS Ltd acquired a new stake in shares of Henry Schein in the 4th quarter worth about $65,000. 94.75% of the stock is owned by institutional investors.

About Henry Schein

(Get Rating)

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Read More

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.